- Nutritional Growth Solutions (NGS) launches a clinical trial of its sports supplement for children
- The eight-week trial will see 50 healthy soccer players aged between eight and 15 years old recruited to determine the efficacy of its new sports supplement when compared to placebo
- The company will invest up to $100,000 in the trial, which it says will add to its “strong pipeline” of products
- Initial results from the study are expected in the third quarter of 2023
- Nutritional Growth Solutions shares are up 5.26 per cent to trade at 6 cents at 12:36 pm AEDT
Nutritional Growth Solutions (NGS) has launched a clinical trial of its sports supplement for children.
The eight-week trial will be a randomised, double-blind, placebo-controlled pilot recruiting up to 50 healthy soccer players aged between eight and 15 years old. The study will look to determine the safety and efficacy of its new sports supplement when compared to a placebo.
The company’s supplement contains whey proteins, amino acids, carbohydrates, fats, and micronutrients.
During the trial, the company will run multiple tests, including 10-metre and 20-metre sprints, countermovement jumps, agility and endurance tests, anthropometric assessments of height, weight and BMI, and assess body composition.
“This trial marks our first step into the growing sports supplements market, and we look forward to offering active children a safe, effective supplement, which was designed especially for them,” CEO and Managing Director Liron Fendell said.
“Based on extensive research, NGS has formulated an innovative nutritional supplement, aimed at completion of the high nutritional requirements of adolescent athletes to help them improve their body composition, exercise performance and general health.”
The company will invest up to $100,000 in the trial, adding to its “strong pipeline” of products.
Initial results from the trial are expected in the third quarter of 2023.
Nutritional Growth Solutions shares were up 5.26 per cent to trade at 6 cents at 12:36 pm AEDT.